Previous 10 | Next 10 |
Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board World-renowned scientist specializing in oncolytic viruses and immuno-oncology PR Newswire SAN DIEGO and CALGARY, AB, Oct. 19, 2020 SAN DIEGO and CALGARY, AB , Oct. ...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 8, 2020 – USA News Group – A newly released report titled “Immunotherapy Drugs Market by Type, Therapy Area, End User – Global Forecast to 2025” fo...
Oncolytics Biotech® to Participate in BIO Investor Forum Digital Canada NewsWire SAN DIEGO and CALGARY, AB, Oct. 7, 2020 SAN DIEGO and CALGARY, AB , Oct. 7, 2020 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announc...
SAN DIEGO and CALGARY, Alberta , Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September: LD Micro 500 Virtual Investor Co...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
CytoDyn advances enrolment in Phase 3 COVID-19 trial CytoDyn Inc. ( CYDY ) announced that it has completed the enrollment for Phase 3 trial for COVID-19 patients with severe-to-critical symptoms. The trial is now eligible for an interim analysis following the 28-day phase. Leronlimab (PR...
August 26, 2020 Palm Beach, FL –August 26, 2020 – Although various market revenue projections may differ in the total dollar figures, the reports in the triple negative breast cancer (TNBC) treatment market all predict a sustainable growth oner the next several years...
Oncolytics Biotech (NASDAQ: ONCY ) has dosed first patient in Phase 2 IRENE study of Company's pelareorep in combination with Incyte's (NASDAQ: INCY ) anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in unresectable locally advanced or metastatic triple-negative breast ...
- Expansion of Oncolytics' lead breast cancer program into a new disease subtype - Seek synergies between pelareorep and retifanlimab checkpoint inhibitor SAN DIEGO, Calif. and CALGARY, Alberta , Aug. 26, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ...
In the fight against some of the most challenging forms of cancer, AstraZeneca PLC (NYSE:AZN) recently placed a giant $6 billion bet on an antibody-drug conjugate (ADC) called DS-1062 from Japanese developers Daiichi Sankyo. The move signalled AZ's confidence that this solid tumor drug coul...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Canada NewsWire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report ove...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Canada NewsWire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast ca...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...